Q3 EPS Forecast for United Therapeutics Increased by Analyst

Posted by Francis Steltz on Aug 18th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Free Report) – Equities research analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for United Therapeutics in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $6.60 per share for the quarter, up from their previous estimate of $6.08. The consensus estimate for United Therapeutics’ current full-year earnings is $26.33 per share. HC Wainwright also issued estimates for United Therapeutics’ FY2026 earnings at $26.56 EPS, FY2027 earnings at $30.30 EPS, FY2029 earnings at $46.03 EPS and FY2030 earnings at $55.98 EPS.

Several other equities analysts have also recently issued reports on UTHR. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Bank of America decreased their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Check Out Our Latest Report on UTHR

United Therapeutics Trading Up 1.8%

Shares of NASDAQ UTHR opened at $508.48 on Monday. The firm has a fifty day simple moving average of $535.22 and a two-hundred day simple moving average of $536.38. United Therapeutics has a 12 month low of $302.19 and a 12 month high of $609.35. The firm has a market capitalization of $21.81 billion, a PE ratio of 18.19, a price-to-earnings-growth ratio of 1.69 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.41 earnings per share.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $565.98, for a total transaction of $5,376,810.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,929,547.74. This represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $564.11, for a total transaction of $5,641,100.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,648,140.36. This trade represents a 34.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 452,575 shares of company stock valued at $246,248,389. 8.60% of the stock is owned by insiders.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently made changes to their positions in UTHR. Arjuna Capital raised its holdings in United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after acquiring an additional 18 shares during the last quarter. Sage Rhino Capital LLC increased its holdings in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC increased its holdings in shares of United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 24 shares in the last quarter. Meeder Advisory Services Inc. raised its stake in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 26 shares during the last quarter. Finally, Independent Advisor Alliance raised its stake in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after purchasing an additional 27 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.